Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Erin Bryant

Physician Assistant, Surgical Lowville, NY Physician Assistant

NPI 1649315060 CMS profile 10617925

7785 N State St Ste G-30, Lowville, NY 13367

Open in the dashboard

General payments

$3,975

184 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erin Bryant of Lowville, NY is reported in the CMS Open Payments database as having received $3,975 across 184 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,051 42
2024 General $1,237 58
2023 General $916 44
2022 General $545 28
2021 General $226 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erin Bryant
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Erin Bryant were reported at $1,051. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Erin Bryant Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $226 $111 $36–$285 $132
2022 $545 $126 $44–$350 $149
2023 $916 $137 $47–$355 $160
2024 $1,237 $146 $49–$384 $164
2025 $1,051 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $685 24 payments
  2. AbbVie, Inc. $387 20 payments
  3. Lilly USA, LLC $377 17 payments
  4. Sun Pharmaceutical Industries Inc. $361 14 payments
  5. Regeneron Healthcare Solutions, Inc. $308 14 payments
  6. Amgen Inc. $281 13 payments
  7. UCB, Inc. $274 13 payments
  8. Pfizer Inc. $256 14 payments
  9. Novartis Pharmaceuticals Corporation $207 12 payments
  10. Incyte Corporation $189 10 payments
  11. Other $650 33 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,441 178 payments
  2. Education $534 6 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $672 23 payments
  2. TALTZ $377 17 payments
  3. Otezla $281 13 payments
  4. OLUMIANT $245 11 payments
  5. DUPIXENT Immunology $221 9 payments
  6. DUPIXENT Inflammation And Immunology $220 11 payments
  7. Bimzelx $219 10 payments
  8. CIBINQO $215 12 payments
  9. RINVOQ $198 9 payments
  10. ILUMYA $196 10 payments
  11. Other $1,807 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,194

Median for Physician Assistant: 241

Drug cost

$1,100,317

Median for Physician Assistant: $4,110

Branded share of claims

13.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 54 $288,534
Cosentyx Sensoready (2 Pens) Secukinumab Brand 20 $257,096
Humira(Cf) Pen Adalimumab Brand 16 $209,946
Cosentyx Unoready Pen Secukinumab Brand 19 $161,595
Otezla Apremilast Brand 26 $150,041
Pimecrolimus Generic 33 $9,933
Clobetasol Propionate Generic 61 $3,721
Triamcinolone Acetonide Generic 138 $2,144
Fluorouracil Generic 29 $2,026
Clindamycin Phosphate Generic 37 $1,990

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$45,826

Medicare's payments for the services billed

Medicare patients

407

Average age 74

Services billed

1,611

213 women, 194 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 50%
Diabetes 25%
Chronic kidney disease 20%
Ischemic heart disease 18%
Cancer 15%
Depression 15%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $174
$174 — —
VTAMA
  • Dermavant Sciences, Inc. $135
$135 — —
Otezla
  • Amgen Inc. $132
$132 26 —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $62
  • GENZYME CORPORATION $23
$84 54 —
RINVOQ
  • AbbVie, Inc. $78
$78 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

184 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record